Would you offer neoadjuvant chemoimmunotherapy per KEYNOTE 522 for a patient with clinical stage IIB triple-negative breast cancer with apocrine histology or recommend surgery first?

Apocrine subtype of TNBC typically has a better prognosis but a poorer response to chemotherapy. Since this is a rarer subtype, most of the evidence comes from real-world experience and anecdotal reports. Smaller data sets have suggested that AC-T may not be needed in these patients and docetaxel an...

Precisely because this is a rare subtype, neoadjuvant chemo immunotherapy should be used, otherwise we are blind to the outcome.

Triple negative disease biology supports this approach.

In ER-negative disease, neoadjuvant therapy should be the primary strategy because path CR correlates with outcome ...